174 related articles for article (PubMed ID: 12556646)
21. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
[TBL] [Abstract][Full Text] [Related]
23. Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension.
Heckman GA; Psaty BM
ACP J Club; 2003; 139(3):A15; author reply A15. PubMed ID: 14594435
[No Abstract] [Full Text] [Related]
24. [ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].
Slany J
Wien Klin Wochenschr; 2003 Mar; 115(5-6):149-51. PubMed ID: 12741071
[No Abstract] [Full Text] [Related]
25. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
[TBL] [Abstract][Full Text] [Related]
26. Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Scott I; Stowasser M
Intern Med J; 2003 Jul; 33(7):327-30. PubMed ID: 12823686
[No Abstract] [Full Text] [Related]
27. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
[TBL] [Abstract][Full Text] [Related]
28. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Kuwajima I
Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
[No Abstract] [Full Text] [Related]
29. The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
Vidt DG
Cleve Clin J Med; 2003 Mar; 70(3):263-9. PubMed ID: 12678218
[TBL] [Abstract][Full Text] [Related]
30. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.
Wang SY; Hanna JM; Gongal P; Onuma OK; Nanna MG
Am Heart J; 2022 Dec; 254():30-34. PubMed ID: 35932912
[TBL] [Abstract][Full Text] [Related]
31. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Ernst ME; Davis BR; Soliman EZ; Prineas RJ; Okin PM; Ghosh A; Cushman WC; Einhorn PT; Oparil S; Grimm RH;
J Am Soc Hypertens; 2016 Dec; 10(12):930-938.e9. PubMed ID: 27938852
[TBL] [Abstract][Full Text] [Related]
32. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
[TBL] [Abstract][Full Text] [Related]
33. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
[TBL] [Abstract][Full Text] [Related]
34. Guidelines for antihypertensive treatment: an update after the ALLHAT study.
Salvetti A; Ghiadoni L
J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S51-4. PubMed ID: 14684673
[TBL] [Abstract][Full Text] [Related]
35. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.
Puttnam R; Davis BR; Pressel SL; Whelton PK; Cushman WC; Louis GT; Margolis KL; Oparil S; Williamson J; Ghosh A; Einhorn PT; Barzilay JI;
JAMA Intern Med; 2017 Jan; 177(1):67-76. PubMed ID: 27893045
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
Piller LB; Simpson LM; Baraniuk S; Habib GB; Rahman M; Basile JN; Dart RA; Ellsworth AJ; Fendley H; Probstfield JL; Whelton PK; Davis BR;
J Gen Intern Med; 2014 Nov; 29(11):1475-83. PubMed ID: 25002161
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial.
Mukhtar O; Cheriyan J; Cockcroft JR; Collier D; Coulson JM; Dasgupta I; Faconti L; Glover M; Heagerty AM; Khong TK; Lip GYH; Mander AP; Marchong MN; Martin U; McDonnell BJ; McEniery CM; Padmanabhan S; Saxena M; Sever PJ; Shiel JI; Wych J; Chowienczyk PJ; Wilkinson IB
Am Heart J; 2018 Oct; 204():102-108. PubMed ID: 30092411
[TBL] [Abstract][Full Text] [Related]
38. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Muntner P; Levitan EB; Lynch AI; Simpson LM; Whittle J; Davis BR; Kostis JB; Whelton PK; Oparil S
J Clin Hypertens (Greenwich); 2014 May; 16(5):323-30. PubMed ID: 24739073
[TBL] [Abstract][Full Text] [Related]
39. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Proschan M; Ford CE; Cutler JA; Graumlich JF; Pavlik V; Cushman WC; Davis BR; Alderman MH; Gordon D; Furberg CD; Franklin SS; Blumenthal SS; Castaldo RS; Preston RA;
Stat Med; 2013 Feb; 32(5):884-97. PubMed ID: 22961832
[TBL] [Abstract][Full Text] [Related]
40. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
